2026年9月15日，石药集团有限公司（01093.HK）发布自愿公告称，公司自主研发的抗体偶联药物（ADC）SYS 6010已被国家药品监督管理局纳入突破性治疗品种名单，拟定适应症为既往接受免疫治疗及含铂化疗失败的复发或转移性驱动基因阴性非鳞状非小细胞肺癌（NSCLC）。
2026年9月15日，石药集团有限公司（01093.HK）发布自愿公告称，公司自主研发的抗体偶联药物（ADC）SYS 6010已被国家药品监督管理局纳入突破性治疗品种名单，拟定适应症为既往接受免疫治疗及含铂化疗失败的复发或转移性驱动基因阴性非鳞状非小细胞肺癌（NSCLC）。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.